Viracta Therapeutics, Inc.

DB:RYI Stock Report

Market Cap: €8.9m

Viracta Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mark Rothera

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage40.5%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Rothera's remuneration changed compared to Viracta Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$1mUS$590k

-US$51m

Sep 30 2023n/an/a

-US$48m

Jun 30 2023n/an/a

-US$53m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$6mUS$167k

-US$49m

Compensation vs Market: Mark's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Rothera (61 yo)

2.3yrs

Tenure

US$1,456,596

Compensation

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Rothera
CEO, President & Director2.3yrsUS$1.46mno data
Darrel Cohen
Chief Medical Officer1.3yrsUS$1.05m0%
€ 0
Susan Perrine
Scientific Founder and Consultant14yrsno datano data
Ronald Berenson
Co-Founder and Consultant14yrsno datano data
George Hillman
Co-Founderno datano datano data
Thalia Papayannopoulou
Co-Founderno datano datano data
Robert Williams
Co-Founderno datano datano data
Douglas Faller
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Michael Faerm
Chief Financial Officerless than a yearno datano data
Cheryl Madsen
Senior Vice President of Regulatory Affairs3.8yrsno datano data
Biljana Nadjsombati
Senior Vice President of Pharmaceutical Development1.9yrsno datano data
Robert McRae
Vice President of Operations & Strategic Alliancesno datano datano data

2.3yrs

Average Tenure

61yo

Average Age

Experienced Management: RYI's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Rothera
CEO, President & Director2.3yrsUS$1.46mno data
Douglas Faller
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Ivor Royston
Director3.8yrsUS$90.76k2.16%
€ 192.1k
Thomas Darcy
Independent Director3.8yrsUS$113.26k0%
€ 0
Ronald Levy
Member of Scientific Advisory Board6.3yrsno datano data
Carl June
Member of Scientific Advisory Board6.3yrsno datano data
Barry Simon
Independent Director3.8yrsUS$110.76k0%
€ 0
Roger Pomerantz
Independent Chairman of the Board3.8yrsUS$210.27k0.32%
€ 28.3k
Lawrence Young
Member of Scientific Advisory Board6.3yrsno datano data
Robert Baiocchi
Member of Scientific Advisory Board6.3yrsno datano data
Pierluigi Porcu
Member of Scientific Advisory Board6.3yrsno datano data
Flavia Borellini
Independent Director3.3yrsUS$92.36k0%
€ 0

3.8yrs

Average Tenure

67yo

Average Age

Experienced Board: RYI's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:56
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viracta Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew BerensLeerink Partners LLC
Hartaj SinghOppenheimer & Co. Inc.